Transthyretin Amyloidosis - Global Drug Forecast and Market Analysis to 2029

Transthyretin Amyloidosis - Global Drug Forecast and Market Analysis to 2029



Amyloidosis is a protein confirmation disorder that results in the build-up of insoluble amyloid proteins in tissues. This build-up can be fatal as it leads to disruption of organ systems and causes oxidative stress within the body. There are various forms of amyloidosis, each associated with the protein involved and the underlying cause of protein mis-folding. Amyloid aggregates affect different organs, most commonly the heart, kidney and liver whilst also affecting the peripheral, autonomic and gastro-intestinal (GI) systems. Most amyloidosis diagnoses are made later in life, with the average patient aged 65 at diagnosis.

Transthyretin Amyloidosis (ATTR) is caused by the transthyretin (TTR) protein and occurs in two forms, either hereditary or wild type. Majority of organ involvement in ATTR is found in the heart and nerves are also affected. Liver transplant is a plausible treatment option for patients with ATTR-m as the liver is the cause of the mutated TTR protein, therefore removing the source of the issue seems to work well. However, a process described as seeding generally means that post-transplantation, the amyloid deposits eventually return due to the amyloid template left by pre-transplant mis-folding.

There are a number of unmet needs in the ATTR market, but drug treatment innovation is on the rise and diagnosis rates are expected to dramatically increase.

Key Highlights

- The main driver of the ATTR market expansion will be the approval and launch of the RNA interference therapeutics both ATTR polyneuropathy and ATTR cardiomyopathy. The approval of other pipeline agents of varying mechanism will also drive growth due to the current scarcity of the ATTR market.
- Another prominent contributor to sales growth the increase in diagnosed prevalence across the 7MM. This increase will be caused by improved understanding and awareness of the disease alongside campaigns by drug developers to increase genetic testing.
- The major global barrier for the ATTR market will be the annual cost of therapy for new pipeline drugs and the lack of options for advanced disease states, the stage at which majority of patients are diagnosed.
- The key market opportunities lie in addressing unmet needs through the development of efficacious therapies for clearing already deposited amyloid and increasing the number of therapies approved for ATTR cardiomyopathy.

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global ATTR therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ATTR therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global ATTR therapeutics market from 2019-2029.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Scope

- Overview of ATTR, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized ATTR therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2019 and forecast for ten years to 2029.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ATTR therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global ATTR market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

- A number of new therapies of varying mechanisms will enter the ATTR market over the forecast period. What strengths do these drugs bring to the market?
- What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the ATTR market?
- The current late-stage ATTR pipeline consists of a number of novel mechanisms such as the RNA interference therapies, Alnylams Onpattro, vutrisiran, and AKCEAs Tegsedi and AKCEA-TTR-LRx, and Eidos TTR stabilizer, AG10. Will the late-stage drugs make a significant impact on the ATTR market?
- Which of these drugs will have the highest peak sales at the highest CAGR, and why?
- The ATTR patient population is currently very small, and the disease is said to hold a falsely perceived rarity. However, the diagnosed patient population is expected to dramatically increase over the forecast period. Why will this occur?
- How will epidemiological changes impact the growth of the future market?

2 Transthyretin Amyloidosis: Executive Summary
2.1 The ATTR Market Will See Dramatic Increases In Patient Population and Approved Therapies From 2019 to 2029
2.2 Multi-Label Drug Approvals Within ATTR Will Fuel Company Revenues
2.3 Rising Patient Populations and a Strong Pipeline Will Bring Considerable Growth to the ATTR Market Over the Forecast Period
2.4 RNAi Therapies Will Dominate the ATTR Market During the Forecast Period
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
5 Epidemiology
6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 US
6.3 5EU
6.4 Japan
7 Competitive Assessment
7.1 Overview
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Increased Awareness and Improved Diagnosis
8.3 Novel Treatments in ATTR Cardiomyopathy
8.4 Treatment Guidelines and Lines of Therapy
8.5 Treatments for Advanced Disease
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Pfizers Portfolio Assessment
10.4 Alnylams Portfolio Assessment
10.5 AKCEAs Portfolio Assessment
10.6 Eidos Portfolio Assessment
10.7 Proclara and Prothena
11 Market Outlook
12 Appendix

List Of Tables

Table 1: Transthyretin Amyloidosis: Key Metrics in the 7MM
Table 2: Classification of Amyloidosis Stages
Table 3: Coutinhos Staging System
Table 4: Risk Factors and Comorbidities for Amyloidosis
Table 5: Country Profile - US
Table 6: Country Profile - 5EU
Table 7: Country Profile - Japan
Table 8: Leading Treatments for ATTR, 2020
Table 9: Pfizers Amyloidosis Portfolio Assessment, 2020
Table 10: Alnylams Amyloidosis Portfolio Assessment, 2020
Table 11: AKCEAs Amyloidosis Portfolio Assessment, 2020
Table 12: Eidos Amyloidosis Portfolio Assessment, 2020
Table 13: ATTR Market - Global Drivers and Barriers, 2019-2029
Table 14: Key Events Impacting Sales for ATTR in the US, 2019-2029
Table 15: ATTR Market - Global Drivers and Barriers in the US, 2019-2029
Table 16: Key Events Impacting Sales for ATTR in the 5EU, 2019-2029
Table 17: ATTR Market - Global Drivers and Barriers in the 5EU, 2019-2029
Table 18: Key Events Impacting Sales for ATTR in Japan, 2019-2029
Table 19: ATTR Market - Global Drivers and Barriers in Japan, 2019-2029
Table 20: Key Historical and Projected Launch Dates for ATTR
Table 21: Key Historical and Projected Patent Expiry Dates for ATTR
Table 22: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List Of Figures

Figure 1: Global Sales for ATTR by Country, 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in ATTR During the Forecast Period
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in ATTR, 2019-2029
Figure 4: Mechanisms of AL and ATTR
Figure 5: 7MM, Diagnosed Prevalence of AL Amyloidosis, Men and Women, All Ages, 2019
Figure 6: 7MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of AL Amyloidosis
Figure 7: 7MM, Sources Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of AL Amyloidosis by Types
Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of AL Amyloidosis
Figure 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of AL Amyloidosis by Mayo Classification Stages
Figure 10: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of AL Amyloidosis with Previous Diagnosis of Multiple Myeloma
Figure 11: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of ATTR-h
Figure 12: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of ATTR-h, ATTR-wt, and AA Amyloidosis
Figure 13: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of ATTR-h Underwent Liver Transplantation
Figure 14: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of ATTR-wt and AA Amyloidosis
Figure 15: 7MM, Diagnosed Incident Cases of AL Amyloidosis, Both Sexes, All Ages, N, 2019
Figure 16: 7MM, Diagnosed Incident Cases of AL Amyloidosis, by Sex, All Ages, N, 2019
Figure 17: 7MM, Diagnosed Incident Cases of AL Amyloidosis by Age, Both Sexes, N, 2019
Figure 18: 7MM, Diagnosed Incident Cases of AL Amyloidosis by Subtypes, All Ages, Both Sexes, N, 2019
Figure 19: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis, Both Sexes, All Ages, N, 2019
Figure 20: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis, by Sex, All Ages, N, 2019
Figure 21: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis by Age, Both Sexes, N, 2019
Figure 22: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis by Types, All Ages, Both Sexes, N, 2019
Figure 23: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis by Mayo Classification Stages, All Ages, Both Sexes, N, 2019
Figure 24: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis with Previous Diagnosis of Multiple Myeloma, All Ages, Both Sexes, N, 2019
Figure 25: 7MM, Diagnosed Incident Cases of ATTR-h, Both Sexes, All Ages, N, 2019
Figure 26: 7MM, Diagnosed Prevalent Cases of ATTR-h, Both Sexes, All Ages, N, 2019
Figure 27: 7MM, Diagnosed Prevalent Cases of ATTR-h Who Underwent Liver Transplantation, All Ages, Both Sexes, N, 2019
Figure 28: 7MM, Diagnosed Incident Cases of ATTR-wt, Both Sexes, All Ages, N, 2019
Figure 29: 7MM, Diagnosed Prevalent Cases of ATTR-wt, Both Sexes, All Ages, N, 2019
Figure 30: 7MM, Diagnosed Incident Cases of AA Amyloidosis, Both Sexes, All Ages, N, 2019
Figure 31: 7MM, Diagnosed Prevalent Cases of AA Amyloidosis, Both Sexes, All Ages, N, 2019
Figure 32: Red Flag Symptoms for ATTR-Associated Cardiomyopathy
Figure 33: Treatment Algorithm for ATTR
Figure 34: Unmet Needs and Opportunities in Transthyretin Amyloidosis
Figure 35: Overview of the Development Pipeline in ATTR
Figure 36: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for ATTR in the 7MM During the Forecast Period
Figure 37: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Approved for the Treatment of ATTR During the Forecast Period
Figure 38: Analysis of the Company Portfolio Gap in ATTR During the Forecast Period
Figure 39: Global (7MM) Sales Forecast by Country for ATTR in 2019 and 2029
Figure 40: Global (7MM) ATTR Sales Forecast by Drug in 2019 and 2029
Figure 41: Sales Forecast by Class for ATTR in the US in 2019 and 2029
Figure 42: Sales Forecast by Class for ATTR in the 5EU in 2019 and 2029
Figure 43: Sales Forecast by Class for ATTR in Japan in 2019 and 2029

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available